Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

To join this study, you need to be an adult, 18 years or older, and have a confirmed diagnosis of extensive stage small cell lung cancer. Your cancer must also have grown or spread after you've already had at least one round of chemotherapy that included specific platinum-based drugs. Doctors will also check that you are well enough to participate, for example, your daily activities aren't too limited by your health.

There are some reasons why you might not be able to join. For instance, if the time between your last chemotherapy and your cancer growing was very short (less than 30 days). Also, if you've already had certain other types of cancer treatment, such as irinotecan, topotecan, or lurbinectedin after your platinum-based chemotherapy, you wouldn't be able to take part. The study also needs to see clear signs of your cancer on scans like CT or MRI.

If you join this study, you'll either receive the new study drug, sacituzumab govitecan, or one of the standard treatments for your condition. You won't get to choose which treatment you receive; this is decided randomly, like flipping a coin. You'll have regular hospital visits, where doctors will give you your medication and conduct various tests. These tests might include blood tests, physical exams, and scans (like CT or MRI) to see how the treatment is working. The exact number of visits and tests will be explained to you by the study team.

Your health will be closely monitored throughout the study. After the main treatment period, you might still have follow-up visits or phone calls to check on your long-term health. The total time you'd be involved in the study can vary, depending on how your treatment progresses, but it will be thoroughly explained to you before you agree to participate.